Lung cancer Early Molecular Assessment trial

Lung cancer Early Molecular Assessment trial - Lung cancer Early Molecular Assessment trial:LEMA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47319

Enrollment

1297

Registered

2016-05-31

Start date

2016-06-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Suspicion of lung carcinoma or established NSCLC but awaiting start of definitive treatment - Written informed consent to undergo diagnostic procedure and molecular analysis of the disease.

Exclusion criteria

Exclusion criteria: - Not motivated to receive any treatment at any point in time. Patients who consider undergoing treatment in the future are eligible.

Design outcomes

Primary

Measure	Time frame
The percentage of patients with EGFR mutation or ALK translocation using the combined tumour tissue and liquid biopsy analysis.	—

Secondary

Measure	Time frame
Secondary endpoints include the test performance of both techniques in different stage of disease, the percentage of patients with a predefined actionable genetic alteration, the costs, and the influence of the liquid biopsies on the diagnostic yield of tissue molecular and pathological analysis.	—

Countries

Netherlands

Outcome results